Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Hilton Capital Management LLC

Hilton Capital Management LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,038 shares of the medical research company’s stock after purchasing an additional 380 shares during the period. Hilton Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,484,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRL. Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after purchasing an additional 53 shares during the last quarter. Fiduciary Financial Group LLC boosted its position in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. M&T Bank Corp lifted its stake in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Cornerstone Investment Partners LLC grew its holdings in Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after buying an additional 69 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent analyst reports. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. JPMorgan Chase & Co. cut their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a research note on Monday, March 3rd. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $198.36.

Charles River Laboratories International Trading Down 2.1 %

Shares of Charles River Laboratories International stock opened at $167.03 on Friday. The firm has a market cap of $8.54 billion, a price-to-earnings ratio of 1,113.55, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77. The company’s 50-day simple moving average is $168.35 and its 200-day simple moving average is $185.07. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).